How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,366 results for

Cushing Response

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Long-term Beneficial Metabolic Effects of Adrenalectomy in Subclinical Cushing's Syndrome of Adrenal Incidentaloma

of saved studies (100). Please remove one or more studies before adding more. Long-term Beneficial Metabolic Effects of Adrenalectomy in Subclinical Cushing's Syndrome of Adrenal Incidentaloma The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details (...) . ClinicalTrials.gov Identifier: NCT01382420 Recruitment Status : Recruiting First Posted : June 27, 2011 Last Update Posted : April 4, 2019 See Sponsor: Samsung Medical Center Collaborators: Asan Medical Center Severance Hospital Konkuk University Medical Center Information provided by (Responsible Party): Jae Hyeon Kim, Samsung Medical Center Study Details Study Description Go to Brief Summary: Objective: To determine the metabolic effects of the adrenalectomy in subclinical Cushing's syndrome of adrenal

2011 Clinical Trials

142. Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease

studies before adding more. Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01374906 Recruitment Status : Completed First Posted : June 16, 2011 Results First Posted : April 11, 2018 Last Update Posted : May 22 (...) , 2018 Sponsor: Novartis Pharmaceuticals Information provided by (Responsible Party): Novartis ( Novartis Pharmaceuticals ) Study Details Study Description Go to Brief Summary: This is a randomized, double-blind, multicenter, phase III study to evaluate the safety and efficacy of 2 dosing regiments of Pasireotide long acting release (LAR) in patients with Cushing's disease. Condition or disease Intervention/treatment Phase Cushing's Disease Drug: pasireotide LAR Drug: SOM230 LAR 30 mg Drug: SOM230

2011 Clinical Trials

143. Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome

of saved studies (100). Please remove one or more studies before adding more. Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01371565 Recruitment Status : Completed First Posted : June 13 (...) , 2011 Results First Posted : November 20, 2013 Last Update Posted : March 18, 2014 Sponsor: Corcept Therapeutics Information provided by (Responsible Party): Corcept Therapeutics Study Details Study Description Go to Brief Summary: This is a compassionate use study. In addition to providing compassionate use access to mifepristone, objectives of the study will be to evaluate the safety and utility of mifepristone in the treatment of the signs and symptoms of endogenous Cushing's syndrome when given

2011 Clinical Trials

144. Safety and Efficacy of LCI699 in Cushing's Disease Patients.

in Cushing's Disease Patients. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01331239 Recruitment Status : Active, not recruiting First Posted : April 8, 2011 Last Update Posted : November 7, 2018 Sponsor: Novartis Pharmaceuticals Information provided by (Responsible Party): Novartis ( Novartis (...) Safety and Efficacy of LCI699 in Cushing's Disease Patients. Safety and Efficacy of LCI699 in Cushing's Disease Patients. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Safety and Efficacy of LCI699

2011 Clinical Trials

145. Effects of Hormone Stimulation on Brain Scans for Cushing s Disease

Stimulation on Brain Scans for Cushing s Disease The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01459237 Recruitment Status : Completed First Posted : October 25, 2011 Last Update Posted : June 14, 2018 Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) Information provided (...) by (Responsible Party): National Institutes of Health Clinical Center (CC) ( National Institute of Neurological Disorders and Stroke (NINDS) ) Study Details Study Description Go to Brief Summary: Background: Cushing s disease can be caused by a tumor of the pituitary gland, a small gland about the size of a pea located at the base of the brain. These tumors produce high levels of hormones, which cause obesity, diabetes, and growth problems. The cure for this type of Cushing s disease is to have surgery

2011 Clinical Trials

146. Does Serum-DXM Increase Diagnostic Accuracy of the Overnight DXM Suppression Test in the Work-up of Cushing's Syndrome?

number of saved studies (100). Please remove one or more studies before adding more. Does Serum-DXM Increase Diagnostic Accuracy of the Overnight DXM Suppression Test in the Work-up of Cushing's Syndrome? (DXM) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01504555 Recruitment Status : Unknown (...) Does Serum-DXM Increase Diagnostic Accuracy of the Overnight DXM Suppression Test in the Work-up of Cushing's Syndrome? Does Serum-DXM Increase Diagnostic Accuracy of the Overnight DXM Suppression Test in the Work-up of Cushing's Syndrome? - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum

2011 Clinical Trials

147. The Influence of AMH on Ovarian Responsiveness to Ovulation Induction With GnRH in Women With PCOS

The Influence of AMH on Ovarian Responsiveness to Ovulation Induction With GnRH in Women With PCOS The Influence of AMH on Ovarian Responsiveness to Ovulation Induction With GnRH in Women With PCOS - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove (...) one or more studies before adding more. The Influence of AMH on Ovarian Responsiveness to Ovulation Induction With GnRH in Women With PCOS The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02673632 Recruitment Status : Unknown Verified February 2016 by Ahmed Mohamed Bahaa Eldin Ahmed, Ain Shams

2016 Clinical Trials

148. Roles of Hippocampal Somatostatin Receptor Subtypes in Stress Response and Emotionality. (Full text)

Roles of Hippocampal Somatostatin Receptor Subtypes in Stress Response and Emotionality. Altered brain somatostatin functions recently appeared as key elements for the pathogenesis of stress-related neuropsychiatric disorders. The hippocampus exerts an inhibitory feedback on stress but the mechanisms involved remain unclear. We investigated herein the role of hippocampal somatostatin receptor subtypes in both stress response and behavioral emotionality using C57BL/6, wild type and sst2 or sst4 (...) and antidepressive effects through distinct mechanisms. Such results are to be accounted for in development of pathway-specific somatostatin receptor agents in the treatment of hypercortisolism (Cushing's disease) and stress-related neuropsychiatric disorders.

2016 Neuropsychopharmacology PubMed

149. Food Intake Response to Short-Term Modifications of Metabolism in Humans

Food Intake Response to Short-Term Modifications of Metabolism in Humans Food Intake Response to Short-Term Modifications of Metabolism in Humans - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Food Intake (...) Response to Short-Term Modifications of Metabolism in Humans The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT02939404 Recruitment Status : Recruiting First Posted : October 20, 2016 Last Update Posted : November 1, 2018 See

2016 Clinical Trials

150. ARMC5 mutations in a large French-Canadian family with cortisol-secreting β-adrenergic/vasopressin responsive bilateral macronodular adrenal hyperplasia. (Full text)

ARMC5 mutations in a large French-Canadian family with cortisol-secreting β-adrenergic/vasopressin responsive bilateral macronodular adrenal hyperplasia. Bilateral macronodular adrenal hyperplasia (BMAH) is a rare cause of Cushing's syndrome (CS) and its familial clustering has been described previously. Recent studies identified that ARMC5 mutations occur frequently in BMAH, but the relation between ARMC5 mutation and the expression of aberrant G-protein-coupled receptor has not been examined

2016 European Journal of Endocrinology PubMed

151. Diagnosis of Cushing's Syndrome (Full text)

posting, and The Endocrine Society Council. At each stage the Task Force incorporated needed changes in response to written comments. Conclusions: After excluding exogenous glucocorticoid use, we recommend testing for Cushing's syndrome in patients with multiple and progressive features compatible with the syndrome, particularly those with a high discriminatory value, and patients with adrenal incidentaloma. We recommend initial use of one test with high diagnostic accuracy (urine cortisol, late night (...) with discordant results, normal responses suspected of cyclic hypercortisolism, or initially normal responses who accumulate additional features over time. SUMMARY OF RECOMMENDATIONS 3.0 Diagnosis of Cushing's syndrome Who should be tested 3.1 We recommend obtaining a thorough drug history to exclude excessive exogenous glucocorticoid exposure leading to iatrogenic Cushing's syndrome before conducting biochemical testing (1⊕⊕⊕⊕). 3.2 We recommend testing for Cushing's syndrome in the following groups

2008 The Endocrine Society PubMed

152. The immunological hazard of Cushing's syndrome. (Full text)

The immunological hazard of Cushing's syndrome. A 24-year-old woman was found to have cryptococcal meningitis and Cushing's syndrome due to an adrenal adenoma. Her meningitis was successfully arrested with fluorouracil. Treatment with metyrapone decreased her cortisol production and produced clinical remission of Cushing's syndrome. On admission her peripheral T lymphocytes were few and hyporeactive. When the overproduction of cortisol ceased the numbers of T lymphocytes and their reactivity (...) returned to normal and she developed in-vitro lymphocyte responsiveness to the cryptococci.

1975 British medical journal PubMed

153. Surgical experience with Cushing's disease. (Full text)

Surgical experience with Cushing's disease. During the period 1952 to 1976 at Vanderbilt University Hospital 119 patients with pituitary-dependent hypercortisolism or Cushing's disease were studied. The less severe cases, which constitute a majority, were treated by pituitary irradiation with endocrinologic cure or improvement in two-thirds of the treated patients. Bilateral total adrenalectomy was reserved for the most severe cases and for failures of pituitary irradiation. In 29 patients (...) with total bilateral adrenalectomy there was one postoperative death. Two of 28 survivors had incomplete relief of hypercortisolism and required additional therapy for its control. One patient with recent operation is improved and another with early improvement died suddenly at home three months after operation. The 24 other adrenalectomized patients, followed 6 months to 20 years, were considered endocrinologic cures of Cushing's disease. One patient in the group who had not received pituitary

1977 Annals of Surgery PubMed

154. Positive Rate-Sensitive Corticosteroid Feedback Mechanism of ACTH Secretion in Cushing's Disease (Full text)

Positive Rate-Sensitive Corticosteroid Feedback Mechanism of ACTH Secretion in Cushing's Disease To define the nature of the disturbance of the corticosteroid feedback mechanism in Cushing's disease, the dynamic aspects of the ACTH response to corticosteroid administration have been studied in patients with Cushing's disease after total adrenalectomy (C.d. post adx.). The results were compared with those obtained in patients with Addison's disease (control group). Different experimental designs (...) for administration of cortisol were chosen to provide extreme variations in the input signal. The response of the system was evaluated by measuring plasma ACTH concentrations (radioimmunoassay) at short time intervals. Infusion of cortisol at constant rate (50 mg/h for 2 h) resulted in a transient, paradoxical rise in ACTH levels with a maximum at 15 min. (315+/-65%, mean+/-SEM). In contrast, in the control group there was an immediate and rapid decrease in ACTH levels with a significant inhibition after 15 min

1979 Journal of Clinical Investigation PubMed

155. CADTH Therapeutic Review Clinical and Economic Overview. Biological Response Modifier Agents for Adults with Rheumatoid Arthritis

CADTH Therapeutic Review Clinical and Economic Overview. Biological Response Modifier Agents for Adults with Rheumatoid Arthritis Canadian Agency for Drugs and Technologies in Health Agence canadienne des médicaments et des technologies de la santé Supporting Informed Decisions CADTH Therapeutic review Clinical and Economic Overview: Biological Response Modifier Agents for Adults with Rheumatoid Arthritis July 2010* *An amendment was made in November 2010 Therapeutic Review CLINICAL (...) AND ECONOMIC OVERVIEW Biological Response Modifier Agents for Adults with Rheumatoid Arthritis July 2010 * * An amendment was made in November 2010 This report is prepared by the Canadian Agency for Drugs and Technologies in Health (CADTH). The report contains a comprehensive review of the existing public literature, studies, materials, and other information and documentation (collectively the ?source documentation?) available to CADTH at the time of report preparation, and was guided by expert input

2010 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

156. Cushing Syndrome

or in those receiving estrogen therapy, but diurnal variation is normal in these patients. Serum ACTH measurement ACTH levels are measured to determine the cause of Cushing syndrome. Undetectable levels, both basally and particularly in response to corticotropin -releasing hormone (CRH), suggest a primary adrenal cause. High levels suggest a pituitary cause or an ectopic source. If ACTH is detectable, provocative tests help differentiate Cushing disease from ectopic ACTH syndrome, which is rarer (...) . In response to high-dose dexamethasone (2 mg po q 6 h for 48 h), the 9 am serum cortisol falls by > 50% in most patients with Cushing disease but infrequently in those with ectopic ACTH syndrome. Conversely, ACTH rises by > 50% and cortisol rises by 20% in response to human or ovine-sequence CRH (100 mcg IV or 1 mcg/kg IV) in most patients with Cushing disease but very rarely in those with ectopic ACTH syndrome (see Table: ). An alternative approach to localization, which is more accurate but more

2013 Merck Manual (19th Edition)

157. Adrenocorticotrophic hormone (ACTH) responsiveness to ghrelin increases after 6 months of ketoconazole use in patients with Cushing's disease: comparison with GH-releasing peptide-6 (GHRP-6). (PubMed)

Adrenocorticotrophic hormone (ACTH) responsiveness to ghrelin increases after 6 months of ketoconazole use in patients with Cushing's disease: comparison with GH-releasing peptide-6 (GHRP-6). In Cushing's disease (CD), adrenocorticotrophic hormone (ACTH)/cortisol responses to growth hormone secretagogues (GHS), such as ghrelin and GHRP-6, are exaggerated. The effect of clinical treatment of hypercortisolism with ketoconazole on ACTH secretion in CD is controversial. There are no studies (...) evaluating ACTH/cortisol responses to GHS after prolonged ketoconazole use in these patients.To compare ghrelin- and GHRP-6-induced ACTH/cortisol release before and after ketoconazole treatment in patients with CD.Eight untreated patients with CD (BMI: 28.5 +/- 0.8 kg/m(2)) were evaluated before and after 3 and 6 months of ketoconazole treatment and compared with 11 controls (BMI: 25.0 +/- 0.8).After ketoconazole use, mean urinary free cortisol values decreased significantly (before: 613.6 +/- 95.2 nmol

2010 Clinical endocrinology

158. Effect of Dexmedetomidine on Plasmatic Cortisol Response in Transsphenoidal Surgery

Effect of Dexmedetomidine on Plasmatic Cortisol Response in Transsphenoidal Surgery Effect of Dexmedetomidine on Plasmatic Cortisol Response in Transsphenoidal Surgery - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before (...) adding more. Effect of Dexmedetomidine on Plasmatic Cortisol Response in Transsphenoidal Surgery The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02549768 Recruitment Status : Unknown Verified October 2016 by Pontificia Universidad Catolica de Chile. Recruitment status was: Recruiting First Posted

2015 Clinical Trials

159. Dose Response and Receptor Selectivity of Beta-blocker Effects on Bone Metabolism

Dose Response and Receptor Selectivity of Beta-blocker Effects on Bone Metabolism Dose Response and Receptor Selectivity of Beta-blocker Effects on Bone Metabolism - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding (...) more. Dose Response and Receptor Selectivity of Beta-blocker Effects on Bone Metabolism The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02467400 Recruitment Status : Completed First Posted : June 10, 2015 Last Update Posted : February 6, 2019 Sponsor: Mayo Clinic Information provided by (Responsible

2015 Clinical Trials

160. Prediction of High Ovarian Response After Assisted Reproductive Techniques

Prediction of High Ovarian Response After Assisted Reproductive Techniques Prediction of High Ovarian Response After Assisted Reproductive Techniques - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Prediction of High Ovarian Response After Assisted Reproductive Techniques (HighART) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02358421 Recruitment Status : Unknown Verified January 2015 by Instituto de Investigacion Sanitaria La Fe. Recruitment status was: Recruiting First Posted : February 9, 2015

2014 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>